Jonathan McNeill
CIK 1824673 · President and COO · last filed 2025-12-17
Jonathan McNeill is a President and COO who has filed 29 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for GLYC, was dated Dec 17, 2025. Across all open-market trades the lifetime net is −$5.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.40M
2
29
-$5.63M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | President and COO | 153,707 | $15.70 | $2.41M | $0 | 2 | 2025-12-17 |
| DYN | Chief Business Officer | 132,106 | $18.19 | $2.40M | -$5.63M | 27 | 2024-08-20 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-17 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +25,507 | $0 | EDGAR |
| 2025-12-10 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-08-20 | DYN | Sell (S) | −2,705 | -$122.1K | EDGAR |
| 2024-06-11 | DYN | Sell (S) | −1,823 | -$57.1K | EDGAR |
| 2024-05-17 | DYN | Sell (S) | −2,774 | -$78.4K | EDGAR |
| 2024-04-04 | DYN | Grant (A) | — | $0 | EDGAR |
| 2024-03-13 | DYN | Mixed | −1,776 | -$2.26M | EDGAR |
| 2024-03-11 | DYN | Sell (S) | −2,434 | -$62.9K | EDGAR |
| 2024-03-01 | DYN | Mixed | — | -$791.0K | EDGAR |
| 2024-01-26 | DYN | Mixed | — | -$475.9K | EDGAR |